Study details
Enrolling now
RA-PRO PRAGMATIC TRIAL
University of Alabama at Birmingham
NCT IDNCT04692493ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
924
Study length
about 7.3 years
Ages
18+
Locations
48 sites in AL, AZ, CA +15
About this study
Researchers are testing whether switching to a non-TNFi biologic or a targeted synthetic DMARD (tsDMARD) improves patient-reported outcomes in people with active rheumatoid arthritis who are already taking a TNFi-biologic. The trial will compare these two treatment options to each other and to continuing the current TNFi-biologic treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take non-TNFi-biologic class
- 2.Take targeted synthetic DMARD class
PhasePhase 3
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Immune